BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7963410)

  • 1. Terbinafine-associated hepatic injury.
    van 't Wout JW; Herrmann WA; de Vries RA; Stricker BH
    J Hepatol; 1994 Jul; 21(1):115-7. PubMed ID: 7963410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection.
    Paredes AH; Lewis JH
    Ann Pharmacother; 2007 May; 41(5):880-4. PubMed ID: 17426078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terbinafine-induced hepatic dysfunction.
    Chambers WM; Millar A; Jain S; Burroughs AK
    Eur J Gastroenterol Hepatol; 2001 Sep; 13(9):1115-8. PubMed ID: 11564966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
    Fontana RJ; Cirulli ET; Gu J; Kleiner D; Ostrov D; Phillips E; Schutte R; Barnhart H; Chalasani N; Watkins PB; Hoofnagle JH
    J Hepatol; 2018 Dec; 69(6):1317-1325. PubMed ID: 30138689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hepatitis attributed to the use of terbinafine].
    Boldewijn OY; Ottervanger JP; Mostart CM; Janssens AR; Calame J; Jonkers GJ
    Ned Tijdschr Geneeskd; 1996 Mar; 140(12):669-72. PubMed ID: 8668241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
    Kwo PY; Cohen SM; Lim JK
    Am J Gastroenterol; 2017 Jan; 112(1):18-35. PubMed ID: 27995906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of laboratory abnormalities in patients prescribed terbinafine for onychomycosis.
    Wang Y; Geizhals S; Lipner SR
    J Am Acad Dermatol; 2021 Feb; 84(2):497-499. PubMed ID: 32387655
    [No Abstract]   [Full Text] [Related]  

  • 8. Terbinafine-induced cholestatic liver disease.
    Lazaros GA; Papatheodoridis GV; Delladetsima JK; Tassopoulos NC
    J Hepatol; 1996 Jun; 24(6):753-6. PubMed ID: 8835752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Terbinafine-induced cholestatic liver injury].
    Shiloah E; Horowiz M; Zecler E
    Harefuah; 1997 Jul; 133(1-2):11-2, 80-1. PubMed ID: 9332048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
    Robles-Diaz M; Garcia-Cortes M; Medina-Caliz I; Gonzalez-Jimenez A; Gonzalez-Grande R; Navarro JM; Castiella A; Zapata EM; Romero-Gomez M; Blanco S; Soriano G; Hidalgo R; Ortega-Torres M; Clavijo E; Bermudez-Ruiz PM; Lucena MI; Andrade RJ; ;
    Liver Int; 2015 Nov; 35(11):2474-82. PubMed ID: 25809419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.
    Mallat A; Zafrani ES; Metreau JM; Dhumeaux D
    Dig Dis Sci; 1997 Jul; 42(7):1486-8. PubMed ID: 9246051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical analysis of 22 patients with drug-induced liver injury caused by traditional Chinese medicine Periploca forrestii Schltr].
    Feng JC; Wang HY; Zhou AQ; Wang DX; Xie Q; Jiang H; Qian GM
    Zhonghua Gan Zang Bing Za Zhi; 2016 Sep; 24(9):692-695. PubMed ID: 27788727
    [No Abstract]   [Full Text] [Related]  

  • 13. A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.
    Kumar K; Gill A; Shafei R; Wright JL
    BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25480138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature.
    Gupta AK; del Rosso JQ; Lynde CW; Brown GH; Shear NH
    Clin Exp Dermatol; 1998 Mar; 23(2):64-7. PubMed ID: 9692307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terbinafine-associated hepatotoxicity.
    Ajit C; Suvannasankha A; Zaeri N; Munoz SJ
    Am J Med Sci; 2003 May; 325(5):292-5. PubMed ID: 12792250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials.
    Church RJ; Watkins PB
    Exp Biol Med (Maywood); 2018 Feb; 243(3):300-307. PubMed ID: 29096561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large dose means significant effect--dose and effect relationship of Chi-Dan-Tui-Huang decoction on alpha-naphthylisothiocyanate-induced cholestatic hepatitis in rats.
    Zhao Y; Ma X; Wang J; Wen R; Jia L; Zhu Y; Li R; Wang R; Li J; Wang L; Li Y; Xiao X
    BMC Complement Altern Med; 2015 Apr; 15():104. PubMed ID: 25889085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.
    Fontana RJ; Hayashi PH; Barnhart H; Kleiner DE; Reddy KR; Chalasani N; Lee WM; Stolz A; Phillips T; Serrano J; Watkins PB;
    Am J Gastroenterol; 2015 Oct; 110(10):1450-9. PubMed ID: 26346867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of severe acute liver injury caused by terbinafine.
    Yan J; Wang X; Chen S
    Int J Clin Pharm; 2014 Aug; 36(4):679-83. PubMed ID: 24986266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute hepatitis associated with terbinafine].
    Vivas S; Rodríguez M; Palacio MA; Cadenas F; Lomo J; Rodrigo L
    Gastroenterol Hepatol; 1997 Nov; 20(9):456-8. PubMed ID: 9445740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.